These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 385328

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Use of 1,2:5,6-dianhydrogalactitol in studies on cell kinetics-directed chemotherapy schedules in human tumors in vivo.
    Barranco SC, Townsend CM, Costanzi JJ, May JT, Baltz R, O'Quinn AG, Leipzig B, Hokanson KM, Guseman LF, Boerwinkle WR.
    Cancer Res; 1982 Jul; 42(7):2899-2905. PubMed ID: 7083178
    [Abstract] [Full Text] [Related]

  • 23. [Clinical observation of 15 cases of chronic myelogenous leukemia treated with 1,2,5,6-dianhydrodulcitol].
    Huang ZG.
    Zhonghua Nei Ke Za Zhi; 1982 Jun; 21(6):356-8. PubMed ID: 6957285
    [No Abstract] [Full Text] [Related]

  • 24. Phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane, and beta-2'-deoxythioguanosine as single agents against advanced measurable tumors of the pancreas. Gastrointestinal Tumor Study Group.
    Cancer Treat Rep; 1985 Jun; 69(6):713-6. PubMed ID: 3926311
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Clinical and pharmacologic evaluation of split-dose intermittent therapy with dianhydrogalactitol.
    Eagan RT, Ames MM, Powis G, Kovach JS.
    Cancer Treat Rep; 1982 Feb; 66(2):283-7. PubMed ID: 7034934
    [Abstract] [Full Text] [Related]

  • 30. Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation.
    Eagan RT, Dinapoli RP, Hermann RC, Groover RV, Layton DD, Scott M.
    Cancer Treat Rep; 1982 Aug; 66(8):1647-9. PubMed ID: 7105055
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Complex evaluation of the effect of some cytostatic hexitol derivatives.
    Holczinger L, Somfai-Relle S, Institoris E, Gáti E, Turi G.
    Oncology; 1980 Aug; 37 Suppl 1():104-8. PubMed ID: 7454197
    [Abstract] [Full Text] [Related]

  • 34. Development and some characteristics of a P388 leukemia strain resistant to 1, 2:5, 6-dianhydrogalactitol.
    Bence J, Somfai-Relle S, Gáti E.
    Eur J Cancer Clin Oncol; 1986 Jul; 22(7):773-80. PubMed ID: 3770035
    [Abstract] [Full Text] [Related]

  • 35. Phase I study of a five-day intermittent schedule for 1,2:5,6-dianhydrogalactitol (NSC-132313).
    Eagan RT, Moertel CG, Hahn RG, Schutt AJ.
    J Natl Cancer Inst; 1976 Jan; 56(1):179-81. PubMed ID: 943554
    [Abstract] [Full Text] [Related]

  • 36. Clinical trials with the hexitol derivatives in the U.S.
    Chiuten DF, Rozencweig M, Von Hoff DD, Muggia FM.
    Cancer; 1981 Feb 01; 47(3):442-51. PubMed ID: 6784907
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Metastatic retinoblastoma and L-phenylalanine mustard-dianhydrogalactitol.
    Helson L, Kitchin FD, Abramson D, Ellsworth RM.
    Anticancer Res; 1982 Feb 01; 2(4):235-8. PubMed ID: 7149653
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.